New schizophrenia drug tested for Long-Term safety in 500 patients

NCT ID NCT07459647

Recruiting now Disease control Sponsor: MapLight Therapeutics Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study is testing a new drug called ML-007C-MA in 500 adults with schizophrenia to see if it is safe and works well over a full year. Participants either recently completed a related study or are new to the trial. The goal is to understand the long-term effects and tolerability of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Site
RECRUITING

Lemon Grove, California, 91945, United States
Clinical Site
RECRUITING

Miami Lakes, Florida, 33016, United States
Clinical Site
RECRUITING

Chicago, Illinois, 60640, United States
Clinical Site
RECRUITING

Staten Island, New York, 10314, United States
Clinical Site
RECRUITING

DeSoto, Texas, 75115, United States

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA